Metraipolis › archive › dc_8fb61fc401e6
Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and Donanemab — Europe PMC PMID:42784125
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42784125
- DOI
- 10.3390/neurolint18090171
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-07T14:21:53.411Z
- SHA-256 of the archived text
d8221df45e8843331edc5c8e72b434a028d90d532e8b745d37b332619f3aa071- Stable URL of this page
https://metraipolis.com/documento/dc_8fb61fc401e6
How to cite
Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and Donanemab — Europe PMC PMID:42784125 — Europe PMC (en), https://europepmc.org/article/MED/42784125 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8fb61fc401e6 (Metraipolis archive dc_8fb61fc401e6, sha256 d8221df45e8843331edc5c8e72b434a028d90d532e8b745d37b332619f3aa071)
BibTeX
@misc{dc8fb61fc401e6,
title = {Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and Donanemab — Europe PMC PMID:42784125},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42784125},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8fb61fc401e6; sha256 d8221df45e8843331edc5c8e72b434a028d90d532e8b745d37b332619f3aa071},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42784125. Agents can read the archived copy with the MCP tool read_document.